These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29354781)

  • 21. In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation.
    Chen B; Guo A; Gao Z; Wei S; Xie YP; Chen SR; Anderson ME; Song LS
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):841-9. PubMed ID: 22722659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca
    Bezzerides VJ; Caballero A; Wang S; Ai Y; Hylind RJ; Lu F; Heims-Waldron DA; Chambers KD; Zhang D; Abrams DJ; Pu WT
    Circulation; 2019 Jul; 140(5):405-419. PubMed ID: 31155924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia.
    Herron TJ; Milstein ML; Anumonwo J; Priori SG; Jalife J
    Heart Rhythm; 2010 Aug; 7(8):1122-8. PubMed ID: 20538074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
    Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
    Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiphoton Imaging of Ca
    Borile G; Zaglia T; E Lehnart S; Mongillo M
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34206855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia.
    Ben Jehuda R; Barad L
    J Atr Fibrillation; 2016; 9(2):1423. PubMed ID: 27909533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.
    Bai Y; Jones PP; Guo J; Zhong X; Clark RB; Zhou Q; Wang R; Vallmitjana A; Benitez R; Hove-Madsen L; Semeniuk L; Guo A; Song LS; Duff HJ; Chen SR
    Circ Res; 2013 Aug; 113(5):517-26. PubMed ID: 23856523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
    Savio-Galimberti E; Knollmann BC
    PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (
    Bongianino R; Denegri M; Mazzanti A; Lodola F; Vollero A; Boncompagni S; Fasciano S; Rizzo G; Mangione D; Barbaro S; Di Fonso A; Napolitano C; Auricchio A; Protasi F; Priori SG
    Circ Res; 2017 Aug; 121(5):525-536. PubMed ID: 28620067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased RyR2 activity is exacerbated by calcium leak-induced mitochondrial ROS.
    Hamilton S; Terentyeva R; Martin B; Perger F; Li J; Stepanov A; Bonilla IM; Knollmann BC; Radwański PB; Györke S; Belevych AE; Terentyev D
    Basic Res Cardiol; 2020 May; 115(4):38. PubMed ID: 32444920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial Ca(2+) uptake by the voltage-dependent anion channel 2 regulates cardiac rhythmicity.
    Shimizu H; Schredelseker J; Huang J; Lu K; Naghdi S; Lu F; Franklin S; Fiji HD; Wang K; Zhu H; Tian C; Lin B; Nakano H; Ehrlich A; Nakai J; Stieg AZ; Gimzewski JK; Nakano A; Goldhaber JI; Vondriska TM; Hajnóczky G; Kwon O; Chen JN
    Elife; 2015 Jan; 4():. PubMed ID: 25588501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload.
    Sedej S; Schmidt A; Denegri M; Walther S; Matovina M; Arnstein G; Gutschi EM; Windhager I; Ljubojević S; Negri S; Heinzel FR; Bisping E; Vos MA; Napolitano C; Priori SG; Kockskämper J; Pieske B
    J Am Coll Cardiol; 2014 Apr; 63(15):1569-79. PubMed ID: 24315909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium signaling in human stem cell-derived cardiomyocytes: Evidence from normal subjects and CPVT afflicted patients.
    Zhang XH; Morad M
    Cell Calcium; 2016 Mar; 59(2-3):98-107. PubMed ID: 26725479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes.
    Novak A; Lorber A; Itskovitz-Eldor J; Binah O
    Rambam Maimonides Med J; 2012 Jul; 3(3):e0015. PubMed ID: 23908839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.